Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Fiche publication
Date publication
novembre 2014
Journal
World journal of surgical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ORRY David
Tous les auteurs :
Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D
Lien Pubmed
Résumé
The purpose of this study is to report prolonged survival in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) managed by chemotherapy and surgery.
Mots clés
Adenocarcinoma, drug therapy, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carcinoma, Pancreatic Ductal, drug therapy, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Liver Neoplasms, drug therapy, Lung Neoplasms, drug therapy, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, drug therapy, Neoplasm Staging, Pancreatectomy, Pancreatic Neoplasms, drug therapy, Peritoneal Neoplasms, drug therapy, Prognosis, Retrospective Studies, Survival Rate
Référence
World J Surg Oncol. 2014 Nov 18;12:347